Lanzotred is indicated for1
- the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
- the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).
- the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
- the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.
The ratio and 90% confidence interval from the log transformed data for the pharmacokinetic parameters AUC0-72 and Cmax of enzalutamide falls within 80% to 125% where Lanzotred is proven to be bioequivalent to the innovator.2
Lanzotred is manufactured in state-of-art facility which was approved by multiple stringent regulatory bodies.2
References: 1) Lanzotred prescribing information, Jul 2022. 2) Lanzotred data on file.
For Healthcare Professional Only